Oligonucleotide Therapeutics: Technology Evolution for Clinically Relevant Tissue Delivery

Basics of intellectual property and patenting

RNA and DNA oligonucleotides with charged backbones commonly cause immune activation, which can be recognized by appropriate in vitro and/or in vivo testing.

Immune Activation by your Therapeutic Oligonucleotide

RNA and DNA oligonucleotides with charged backbones commonly cause immune activation, which can be recognized by appropriate in vitro and/or in vivo testing.